Clinical Trial Update: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating danoprevir in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) for treatment-naive patients with chronic hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Danoprevir (danoprevir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED